As a rheumatologist in St. Clair Shores, I treat patients with serious autoimmune diseases like rheumatoid arthritis, lupus, and psoriatic arthritis — conditions that, not long ago, often meant a lifetime of pain and progressive disability. But thanks to major therapeutic advances, many of my patients are now able to live active, fulfilling lives.

Unfortunately, that progress is now at risk.

Washington is again considering a "Most Favored Nation" (MFN) model — a scheme that would link U.S. medicine prices to the lowest price paid by other industrialized countries. On paper, it may sound like a good way to level the playing field. In reality, it threatens the ability of community-based physicians like me to continue offering essential medical treatments.

The federal government's own anal

See Full Page